Continuous dopaminergic stimulation (CDS)-based treatment in Parkinson's disease patients with motor complications: a systematic review and meta-analysis.

Xie CL, Wang WW, Zhang SF, Gan J, Liu ZG.

Sci Rep. 2014 Aug 12;4:6027. doi: 10.1038/srep06027. Review.

Copper and copper proteins in Parkinson's disease.

Montes S, Rivera-Mancia S, Diaz-Ruiz A, Tristan-Lopez L, Rios C.

Oxid Med Cell Longev. 2014;2014:147251. doi: 10.1155/2014/147251. Review.

The newly discovered Parkinson's disease associated Finnish mutation (A53E) attenuates α-synuclein aggregation and membrane binding.

Ghosh D, Sahay S, Ranjan P, Salot S, Mohite GM, Singh PK, Dwivedi S, Carvalho E, Banerjee R, Kumar A, Maji SK.

Biochemistry. 2014 Oct 21;53(41):6419-21. doi: 10.1021/bi5010365.

In a rush to decide: deep brain stimulation and dopamine agonist therapy in Parkinson's disease.

Djamshidian A, O'Sullivan SS, Tomassini A, Foltynie T, Limousin P, Aviles-Olmos I, Warner TT, Lees AJ, Averbeck BB.

J Parkinsons Dis. 2014;4(4):579-83. doi: 10.3233/JPD-140388.

A PPAR-β/δ agonist is neuroprotective and decreases cognitive impairment in a rodent model of Parkinson's disease.

Das NR, Gangwal RP, Damre MV, Sangamwar AT, Sharma SS.

Curr Neurovasc Res. 2014 May;11(2):114-24.

Improving functional disability and cognition in Parkinson disease: randomized controlled trial.

Peña J, Ibarretxe-Bilbao N, García-Gorostiaga I, Gomez-Beldarrain MA, Díez-Cirarda M, Ojeda N.

Neurology. 2014 Dec 2;83(23):2167-74. doi: 10.1212/WNL.0000000000001043.

N-terminal truncated UCH-L1 prevents Parkinson's disease associated damage.

Kim HJ, Kim HJ, Jeong JE, Baek JY, Jeong J, Kim S, Kim YM, Kim Y, Nam JH, Huh SH, Seo J, Jin BK, Lee KJ.

PLoS One. 2014 Jun 24;9(6):e99654. doi: 10.1371/journal.pone.0099654.

Relation of clinical subtypes in Parkinson's disease with survival.

de Lau LM, Verbaan D, van Rooden SM, Marinus J, van Hilten JJ.

Mov Disord. 2014 Jan;29(1):150-1. doi: 10.1002/mds.25652. No abstract available.

Altered activation in visual cortex: unusual functional magnetic resonance imaging finding in early Parkinson's disease.

Zhao Y, Zheng X, Wang Q, Xu J, Xu X, Zhang M.

J Int Med Res. 2014 Apr;42(2):503-15. doi: 10.1177/0300060513507647.

Wolff-Parkinson-white syndrome mimics a conduction disease.

Marrakchi S, Kammoun I, Kachboura S.

Case Rep Med. 2014;2014:789537. doi: 10.1155/2014/789537.

Community-based adapted tango dancing for individuals with Parkinson's disease and older adults.

Hackney ME, McKee K.

J Vis Exp. 2014 Dec 9;(94). doi: 10.3791/52066. Erratum in: J Vis Exp. 2015;(100):e5733. Hackney, Madeleine [corrected to Hackney, Madeleine E].

Objective Automatic Assessment of Rehabilitative Speech Treatment in Parkinson's Disease.

Tsanas A, Little MA, Fox C, Ramig LO.

IEEE Trans Neural Syst Rehabil Eng. 2014 Jan;22(1):181-90. doi: 10.1109/TNSRE.2013.2293575.

Fetal-cell revival for Parkinson's.

Abbott A.

Nature. 2014 Jun 12;510(7504):195-6. doi: 10.1038/510195a. No abstract available.

[Drug treatment of early-stage (de novo and honeymoon") Parkinson disease]."

Cesaro P, Defebvre L.

Rev Neurol (Paris). 2014 Apr;170(4):237-46. doi: 10.1016/j.neurol.2013.10.015. Review. French.

Neuroprotective Properties of a Standardized Extract from Myracrodruon urundeuva Fr. All. (Aroeira-Do-Sertão), as Evaluated by a Parkinson's Disease Model in Rats.

Calou I, Bandeira MA, Aguiar-Galvão W, Cerqueira G, Siqueira R, Neves KR, Brito GA, Viana G.

Parkinsons Dis. 2014;2014:519615. doi: 10.1155/2014/519615.